Gene therapy with AAV9‐SGPL1 in an animal model of lung fibrosis

Abstract

AbstractIdiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lung that leads rapidly to respiratory failure. Novel approaches to treatment are urgently needed. The bioactive lipid sphingosine‐1‐phosphate (S1P) is increased in IPF lungs and promotes proinflammatory and profibrotic TGF‐β signaling. Hence, decreasing lung S1P represents a potential therapeutic strategy for IPF. S1P is degraded by the intracellular enzyme S1P lyase (SPL). Here we find that a knock‐in mouse with a missense SPL mutation mimicking human disease resulted in reduced SPL activity, increased S1P, increased TGF‐β signaling, increased lung fibrosis, and higher mortality after injury compared to wild type (WT). We then tested adeno‐associated virus 9 (AAV9)‐mediated overexpression of human SGPL1 (AAV‐SPL) in mice as a therapeutic modality. Intravenous treatment with AAV‐SPL augmented lung SPL activity, attenuated S1P levels within the lungs, and decreased injury‐induced fibrosis compared to controls treated with saline or only AAV. We confirmed that AAV‐SPL treatment led to higher expression of SPL in the epithelial and fibroblast compartments during bleomycin‐induced lung injury. Additionally, AAV‐SPL decreased expression of the profibrotic cytokines TNFα and IL1β as well as markers of fibroblast activation, such as fibronectin (Fn1), Tgfb1, Acta2, and collagen genes in the lung. Taken together, our results provide proof of concept for the use of AAV‐SPL as a therapeutic strategy for the treatment of IPF. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.